参考资料 [1]Yuqin S, Shuhua Y, Haiyan Y et al. Pirtobrutinib, a Non-Covalent (Reversible) BTK Inhibitor in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor ...

Researchers sought to determine whether BTK inhibitors would be a preferred second-line therapy for younger patients with MCL.

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

Bruton tyrosine kinase (BTK) inhibitors are commonly used in the treatment of hematological cancers. However, approximately 67% of patients with relapsed chronic lymphocytic leukemia (CLL) develop ...

BTK inhibitors increase infection risk in B-cell lymphoma patients, necessitating proactive monitoring and prophylactic strategies. BTK inhibition affects immune functions, impairing pathogen ...

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...

The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or ...

EMA grants PRIME designation to Nurix Therapeutics’ NX-5948 to treat relapsed or refractory chronic lymphocytic leukaemia: San Francisco Friday, November 22, 2024, 16:00 Hrs [IS ...